Based on extensive interviews in China and in Africa over 2 years, the present paper investigates Chinese private direct investment in Africa. Drawing on the Swedish Uppsala model, we explore two mian issues. First, d...Based on extensive interviews in China and in Africa over 2 years, the present paper investigates Chinese private direct investment in Africa. Drawing on the Swedish Uppsala model, we explore two mian issues. First, do Chinese private enterprises follow the linear mode to invest in Africa？ Second, if not, how do they go out and develop their investments, and who helps them overcome the obstacles to investing in Africa？ We find that very few Chinese private enterprises follow a linear internationalization process, and most depend on the local overseas Chinese network and other networks to facilitate their entry into the host market. The reason lies in that Chinese private enterprises are still at the early stage of internationalization. Entrepreneurship is one of the most important ownership advantages of Chinese private enterprises investing in Africa.展开更多
This paper examines the privatization, implemented by the effects of state-owned enterprises （SOE） Chinese government in the 1990s, on enterprise efficiency for a sample of non-privatized SOEs and privatized ex-SOEs...This paper examines the privatization, implemented by the effects of state-owned enterprises （SOE） Chinese government in the 1990s, on enterprise efficiency for a sample of non-privatized SOEs and privatized ex-SOEs. The study calculates input-oriented DEA meta-frontier efficiency scores, after accounting for heterogeneity in technology across groups. These scores are used to test whether or not one group＇s technology dominates the other. A measure of additional input saving is also provided if these enterprises have access to unrestricted rneta-technology. The analysis of the Chinese pharmaceutical industry reveals that privatization has not improved enterprise efficiency, at least in the short run. Almost 56% of inputs could be proportionally saved if these privatized ex-SOEs had been efficient, relative to the recta-production technology while non-privatized SOEs could proportionally save only 51%. Privatized ex-SOEs had less ability to access to meta-technology. This finding could be explained by subsequent observations that China, at the time of our analysis, did not have well-established intellectual property rights and formal drug approval procedures; these two factors are important driving forces for developing joint ventures with foreign investors to gain additional capital funding and technology transfer. Broadly speaking, our results are consistent with the subsequent shakeup in the Chinese pharmaceutical industry.展开更多
文摘Based on extensive interviews in China and in Africa over 2 years, the present paper investigates Chinese private direct investment in Africa. Drawing on the Swedish Uppsala model, we explore two mian issues. First, do Chinese private enterprises follow the linear mode to invest in Africa？ Second, if not, how do they go out and develop their investments, and who helps them overcome the obstacles to investing in Africa？ We find that very few Chinese private enterprises follow a linear internationalization process, and most depend on the local overseas Chinese network and other networks to facilitate their entry into the host market. The reason lies in that Chinese private enterprises are still at the early stage of internationalization. Entrepreneurship is one of the most important ownership advantages of Chinese private enterprises investing in Africa.
文摘This paper examines the privatization, implemented by the effects of state-owned enterprises （SOE） Chinese government in the 1990s, on enterprise efficiency for a sample of non-privatized SOEs and privatized ex-SOEs. The study calculates input-oriented DEA meta-frontier efficiency scores, after accounting for heterogeneity in technology across groups. These scores are used to test whether or not one group＇s technology dominates the other. A measure of additional input saving is also provided if these enterprises have access to unrestricted rneta-technology. The analysis of the Chinese pharmaceutical industry reveals that privatization has not improved enterprise efficiency, at least in the short run. Almost 56% of inputs could be proportionally saved if these privatized ex-SOEs had been efficient, relative to the recta-production technology while non-privatized SOEs could proportionally save only 51%. Privatized ex-SOEs had less ability to access to meta-technology. This finding could be explained by subsequent observations that China, at the time of our analysis, did not have well-established intellectual property rights and formal drug approval procedures; these two factors are important driving forces for developing joint ventures with foreign investors to gain additional capital funding and technology transfer. Broadly speaking, our results are consistent with the subsequent shakeup in the Chinese pharmaceutical industry.
